F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause

Roni Caryn Rabin / nytimes - The benefits of hormone replacement have been underappreciated, Dr. Marty Makary, the agency’s commissioner, said on Monday. Critics described evidence for the change as insufficient.

AI Summary: In a bold policy pivot, the FDA will lift long‑standing black box warnings on hormone treatments for menopause. The decision – made without an official advisory committee’s input – updates labeling to better reflect current risk–benefit assessments, leaving critics to wonder if caution has finally given way to progress.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days

FDA Abortion Pill Decisions Rooted in Science / 4 months

FDA loosens data restrictions to accelerate drug reviews / 5 months

FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 6 months

Life-extending prostate cancer drug to be offered to thousands in England / 4 months

OpenAI debuts ChatGPT Health for integrated wellness data / 4 months

DEA extends telehealth controlled substance flexibilities for 2026 / 4 months